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Abstract: 
MicroRNAs (miRNAs) are members of a family of non-coding RNAs of 8-24 nucleotide RNA molecules that regulate target 
mRNAs. The first miRNAs, lin-4 and let-7, were first discovered in the year 1993 by Ambros, Ruvkun, and co-workers while 
studying development in Caenorhabditis elegans. miRNAs can play vital functions form C. elegans to higher vertebrates by typical 
Watson-Crick base pairing to specific mRNAs to regulate the expression of a specific gene. It has been well established that 
multicellular eukaryotes utilize miRNAs to regulate many biological processes such as embryonic development, proliferation, 
differentiation, and cell death. Recent studies have shown that miRNAs may provide new insight in cancer research. A recent study 
demonstrated that more than 50% of miRNA genes are located in fragile sites and cancer-associated genomic regions, suggesting 
that miRNAs may play a more important role in the pathogenesis of human cancers. Exploiting the emerging knowledge of 
miRNAs for the development of new human therapeutic applications will be important. Recent studies suggest that miRNA 
expression profiling can be correlated with disease pathogenesis and prognosis, and may ultimately be useful in the management of 
human cancer. In this review, we focus on how miRNAs regulate tumorigenesis by acting as oncogenes and anti-oncogenes in 
higher eukaryotes. 
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Background: 
Cancer is caused by misappropriate expression of genes and is 
one of the most lethal diseases affecting human population. 
The first proof that miRNAs are involved in cancer came 
from the finding that miR-15a and miR-16-1 are down-
regulated or deleted in most patients with chronic 
lymphocytic leukemia (CLL) [1]. The use of miRNA 
microarrays made possible large profiling studies in cancer 
patients, confirming that miRNAs are differentially expressed 
in normal and tumor samples [2].  
 
In this review, we briefly described miRNA biogenesis and 
the principle approaches for studying the function of miRNAs 
in cancers. Furthermore, we focused on miRNAs as 
oncogenes and tumor suppressors by outlining the evidence 
for the involvement of miRNAs in numerous human cancers, 
with several specific examples from both experimental and 
clinical analysis. To exemplify how miRNA can be useful, 
potential application of miRNAs as biomarkers, diagnosis, 
and potential therapeutic tools of human cancers are 
discussed. Finally, we provide an overview of some of the 
past and potential future aspects and present a broad overview 
of this rapidly growing field. 
 
 
 
MicroRNA biogenesis and mechanism  
miRNAs are encoded in the genome and are transcribed by 
RNA polymerase II (pol II) as long precursor transcripts, 
which are known as primary miRNAs (pri-miRNAs) of 
several kilobases in length [3]. Mature miRNAs are generated 
from pri-miRNAs by sequential processing steps. The pri-
miRNAs are initially recognized by the microprocessor 
complex in the nucleus, whose core components are the 
RNase-III enzyme Drosha and its binding partner DGCR8 [4-
7]. The microprocessor complex excises the stem-loop hairpin 
structure that contains the miRNA, a 60-80 nucleotide 
intermediate termed precursor miRNA (pre-miRNA). The 
pre-miRNA is recognized by the nuclear export factor 
Exportin-5, which transports it to the cytoplasm [8-10]. Pre-
miRNAs are rapidly exported to the cytoplasm by the nuclear 
export factor exportin 5 which uses Ran-GTP as a cofactor [8-
10]. Further cytoplasmic processing by dicer, a second RNase 
III enzyme named Dicer performs a second cleavage to 
generate double-stranded 18-24 nucleotide-long [11-14]. One 
of these two strands - the guide strand - is incorporated in an 
ATP-independent manner into a large protein complex known 
as the RNA-induced silencing complex, or RISC, which 
includes as core components the Argonaute proteins (Ago1 - 
4 in humans) [15]. Only one strand of the miRNA duplex 
remains stably associated with RISC. This strand becomes the Bioinformation by Biomedical Informatics Publishing Group                                    open access 
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mature miRNA. The opposite strand, known as the passenger 
strand, is disposed of through two alternative mechanisms. 
When miRNAs are loaded into RISC containing Ago2, the 
only human Ago protein capable of cleaving target mRNAs, 
the passenger strand may be cleaved. Alternatively, RISC 
containing any Ago protein may remove the passenger strand 
via a bypass mechanism that does not require cleavage and 
likely involves duplex unwinding [16-18]. The miRNA guides 
the RISC complex to the target mRNA, which will then be 
subsequently cleaved or translationally silenced. The degree 
of complementarity between an miRNA and its target 
determines the mechanism of silencing ding on the degree of 
sequence complementarity of the miRNA to its target mRNA 
[19-21]. 
 
MicroRNA expression profiling  
Currently, almost all of the miRNA-related studies on cancers 
based on the different expression profile of miRNAs in cancer 
cells vs. normal cells. Differential expression of the candidate 
miRNAs is a good approach to study the function of miRNAs 
in cancer pathogenesis. Knockdown or overexpression of a 
specific miRNA allows studying the specific roles of the 
miRNA in tumorigenesis. Several groups have studied the 
miRNA expression in cancer patients and found that miRNAs 
are differentially expressed in normal and tumor tissues [2]. 
There are several methods have been proposed to conduct this 
study, such as antisense inhibitors, transgenics, northern blot, 
real-time PCR and miRNA microarray.  
 
For cancer studies, it is important to be able to compare the 
expression pattern of all known miRNAs between cancer cells 
and normal cells. Two-color fluorescence-based microarray 
technology (DNA microarray) has been widely used to detect 
gene expression simultaneously. miRNA microarray offers 
detection of multiple differentially expressed miRNAs in 
cancers, may become a technique in cancer epidemiology and 
early cancer detection. Murakami and colleagues have 
exploited this method to detect precursors and mature 
miRNAs in 25 pairs of hepatocellullar carcinoma and adjacent 
non-tumoral tissue, and nine chronic-hepatitis tissues [22]. 
Their analysis showed a small number of miRNAs associated 
with differentiation state of the tumors, proposing that these 
miRNAs might contribute to both oncogenesis and loss of 
differentiation  [22]. Microarray profiling was also used to 
study miRNAs that are differentially expressed in breast 
cancer. Researchers have reported results from 76 breast-
cancer patients and ten normal breast samples and found 29 
miRNAs, the expression of which is significantly deregulated 
in tumors [23]. A set of 15 miRNAs correctly predicted the 
nature of the breast-cancer sample analyzed with 100% 
accuracy. The highly up or downregulated miRNAs were 
miR-125b, miR-145, miR-21 and miR-155. Moreover, the 
expression of miRNAs was correlated with specific breast-
cancer pathological features such as estrogen-receptor status, 
tumor stage, vascular invasion and proliferative index [23]. 
Overall, these studies have evidenced the existence of miRNA 
signatures that are tissue and tumor-specific and allow us to 
classify, diagnose and, in some cases, predict outcome 
accurately in cancer patients. 
 
microRNAs as tumor suppressor genes 
In oncogenesis, some miRNAs are downregulated in 
cancerous cells. These types of miRNAs are considered tumor 
suppressor genes (Table 1 in supplementary material). Tumor 
suppressor miRNAs generally prevent tumor development by 
negatively inhibiting oncogenes and/or genes that control cell 
differentiation or apoptosis. At present, various miRNAs are 
considered as tumor suppressor genes, for example, miR-15a 
and miR-16–1. Studies have shown that tumor suppressor role 
from frequent downregulation of miR-15a and miR-16-1 in 
CLL (Chronic lymphocytic leukemia) patients [1]. These two 
miRNAs are located in a commonly deleted area in CLL and 
both miR-15a and miR-16-1 act as tumor suppressors by 
downregulating B-cell CLL/lymphoma 2 (BCL2), a gene that 
is often upregulated in CLL [24, 25]. Therefore, 
downregulation of miR-15a and miR-16-1, which is mainly 
due to a genetic deletion, might promote B-cell proliferation 
in CLL, a disease where the main feature is an abnormal 
neoplastic proliferation of B cells.  
 
The second evidence that suggests a role of tumor suppressor 
for miRNAs came from the observation of frequent 
downregulation of let-7 in lung cancer [26]. In humans, let-7 
is located at a chromosome region that is usually deleted in 
human cancers [27]. Let-7 was initially observed in C. 
elegans. let-7 is one of the beginning members of the miRNA 
family  [28, 29]. Improper expression of let-7 results in 
oncogenic loss of differentiation. Let-7 family members map 
to fragile sites associated with lung, breast, urothelial and 
cervical cancer [27].  
 
microRNAs as oncogenes  
miRNAs that are significantly over-expressed in tumors may 
be considered as oncogenes. All of them appear to function as 
oncogenes; nevertheless, only a few of them have been well 
characterized. These oncogene miRNAs, called “oncomirs”, 
usually promote tumor development by negatively inhibiting 
tumor suppressor genes and/or genes that control cell 
differentiation or apoptosis. Several studies and clinic analysis 
suggest that miRNAs may function as a novel class of 
oncogenes or tumor suppressor genes (Figure 1). miR-17-92 
is a classic example for an oncogenic miRNA. mir-17-92 
cluster is a miRNA polycistron located at chromosome 
13q31-32, a region that is commonly amplified in B-cell 
lymphoma, was upregulated in 65% of the B-cell lymphoma 
samples examined [30, 31]. Compared with normal tissues, 
the expression of mir-17-92 is significantly increased in 
several cancer types, including lung cancer and lymphomas, 
especially in their most aggressive forms, such as small-cell 
lung cancer and human B-cell lymphomas [30, 31]. The miR-
17-92 cluster also appears to enhance lung cancer cell growth 
[30]. To test whether this polycistron contributes to cancer 
formation, He and colleagues have used a well-characterized 
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Using retroviral transduction, the authors overexpressed the 
miR-17-92 cluster in hematopoietic stem cells from mice that 
carry the MYC transgene. The enforced expression of the 
miR-17-92 cluster acted, together with MYC expression, to 
significantly accelerate the formation of lymphoid 
malignancies [31]. Co-expression of miR-17-19b, a truncated 
portion of miR-17-92, strongly accelerated lymphomagenesis 
[32]. Computational studies have shown that over 600 genes 
were targeted by miR-19a and miR-20, two members of miR-
17-92 cluster [33, 34]. Tumor suppressor genes PTEN 
(phosphatase and tensin homolog deleted on chromosome ten) 
and RB2 were predicted to be targeted by miR-17-92 cluster 
[35]. PTEN promotes apoptosis through the P13K-Akt-PKB 
pathway [32]. However, there was no biological evidence that 
PTEN and RB2 are right targets of the miR-17-92 cluster. The 
oncogenic role of the miR-17-92 cluster is further supported 
by profiling studies showing upregulation of this cluster in B-
cell CLL [36] and in solid cancers [30, 37]. It is logical to 
suggest that these miRNAs have distinct roles in distinct cell 
types, as was formerly proposed for well-known genes that 
encode tumor suppressors or oncogenes [38]. These studies 
suggest that mir-17-92 functions as an oncogene in humans 
and other animal models.  
 
 
Figure 1: The biogenesis and mechanism of human miRNA. The biogenesis of miRNA involves several enzymatic steps. 
Following transcription by RNA polymerase II (Pol II), capped and poly-adenylated primary miRNA transcripts (pri-miRNAs) are 
processed in the nucleus by the endonuclease Drosha into one or more premiRNAs (1). This pre-miRNA is exported from the 
nucleus to the cytoplasm and processed by another RNase enzyme called Dicer, which produces a transient 19-24 nucleotide duplex 
(2). Duplex is cleaved (3) and only one strand of the miRNA duplex (mature miRNA) is incorporated into into the RISC (RNA 
induced silencing complex), which retains only the single-stranded mature miRNA (4). This miRNA-programmed RISC negatively 
regulates the stability and/or translation of target mRNAs depending on the degree of complementary sites between the miRNA and 
its target.  
 
Conclusion: 
Understanding of the role of miRNAs is allowing new 
insights on the molecular basis of cancers, and new 
biomarkers for cancer diagnoses and cancer therapy. The 
elucidation of how global miRNA expression contributes to 
phenotypic outcomes will be important to disease and/or 
signaling pathways that affect miRNA function as well as 
environmental or genetic factors that affect miRNA 
expression. Once this information is available, a rational 
approach can be taken to develop new therapeutic strategies 
that aim to correct inherited and acquired diseases. It will also 
be important to study combinatorial effects of multiple 
miRNAs on target gene expression [33]. The technological 
development in the field, particularly in the realm of bead-
based flow cytometry, single molecule detection and Bioinformation by Biomedical Informatics Publishing Group                                    open access 
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massively parallel sequencing coupled with the miRAGE 
approach, may help launch an automatable, high-speed 
process for miRNA profiling in the near future [39-41]. Even 
though the discovery of miRNAs will probably change the 
landscape of cancer genetics, more work is required to 
understand the mechanism by which miRNAs contribute to 
cancer origin and progression. 
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Supplementary material 
 
microRNAs Targets  Cancer  types 
Oncogenes 
miR-221/222  cKIT  Papillary thyroid cancer; glioblastoma 
miR-372-373  LATS2  Germ cell tumors 
miR-191 Unknown Colorectal  cancer; non–small cell lung cancer; pancreatic cancer; stomach cancer; 
prostate cancer 
miR-17-92  RAS  Non–small cell lung cancer 
Let-7 MYC  Lung  cancer 
BIC/miR155  AT1R  B-cell lymphoma, breast, colon, lung and thyroid 
    
Tumor suppressors 
miR-15a/16 BCL-2  Chronic  lymphocytic  leukemia (B cell); pituitary tumors 
miR-143/145  ERK5; MAPK7  Colorectal cancer; breast cancer 
miR-125b Unknown  Breast  cancer 
miR-106a  RB-1  Colorectal cancer; pancreatic cancer; prostate cancer 
Table 1: Role of miRNAs as oncogene and tumor suppressors with their cancer association. 
  
 